Aurinia Pharmaceuticals Inc (AUPH)vsRegeneron Pharmaceuticals Inc (REGN)
AUPH
Aurinia Pharmaceuticals Inc
$14.37
+1.13%
HEALTHCARE · Cap: $1.91B
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 4967% more annual revenue ($14.34B vs $283.06M). AUPH leads profitability with a 101.5% profit margin vs 31.4%. AUPH trades at a lower P/E of 6.9x. AUPH earns a higher WallStSmart Score of 68/100 (B-).
AUPH
Strong Buy68
out of 100
Grade: B-
REGN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+85.0%
Fair Value
$96.88
Current Price
$14.37
$82.51 discount
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 60 in profit
Keeps 102 of every $100 in revenue as profit
Strong operational efficiency at 55.7%
Earnings expanding 15073.0% YoY
Conservative balance sheet, low leverage
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Areas to Watch
Smaller company, higher risk/reward
Distress zone — elevated risk
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 101.5% and operating margin at 55.7%. Revenue growth of 28.8% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bear Case : AUPH
The primary concerns for AUPH are Market Cap, Altman Z-Score.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
AUPH profiles as a growth stock while REGN is a value play — different risk/reward profiles.
AUPH carries more volatility with a beta of 1.59 — expect wider price swings.
AUPH is growing revenue faster at 28.8% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
AUPH scores higher overall (68/100 vs 58/100), backed by strong 101.5% margins and 28.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?